Naeve Gregory S. 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jan 4, 2019
Insider Transaction Report
Form 4
Naeve Gregory S.
Sr. VP, Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2019-01-02+2,031→ 15,434 total - Exercise/Conversion
Restricted Stock Units
2019-01-02−2,031→ 6,094 total→ Common Stock (2,031 underlying) - Tax Payment
Common Stock
2019-01-02$3.33/sh−993$3,307→ 14,441 total
Footnotes (3)
- [F1]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 8,125 shares.
- [F3]The RSUs vest in four equal annual installments beginning on January 2, 2019.